Calidi Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Calidi Biotherapeutics, Inc. (CLDI) on January 8, 2024, covering events as of January 5, 2024. The Company is a Delaware corporation incorporated as an emerging growth company, with principal executive offices in San Diego, California. The filing primarily serves to disclose a letter from the Chairman and CEO to stockholders regarding recent milestones, clinical progress, and future plans.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate communication rather than a financial statement update.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The primary event is the issuance of a letter to stockholders (Exhibit 99.1) detailing operational updates.
Guidance, Outlook, and Risks
Management commentary is contained within the attached "Letter to Stockholders" (Exhibit 99.1), which addresses recent milestones, clinical progress, and future plans. The filing explicitly states that the information is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section nor incorporated by reference in other filings. No specific risks, contingencies, or unusual items are detailed in the body of this 8-K.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Letter to Stockholders) for specific details on clinical progress and future strategic plans.
- Note that the information in this filing is furnished and not deemed filed under Section 18 of the Exchange Act.
- Verify the Company's status as an emerging growth company and its listing on NYSE American LLC under symbols CLDI and CLDIWS.
- Check subsequent filings for any financial data or updates referenced in the CEO's letter.